Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SANA BIOTECHNOLOGY, INC.

(SANA)
  Report
Delayed Nasdaq  -  04:00 2022-10-04 pm EDT
6.460 USD   +7.49%
09/13Transcript : Sana Biotechnology, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 02:55 PM
CI
09/09Sana Biotechnology to Present at September 2022 Investor Conferences
GL
09/09Sana Biotechnology to Present at September 2022 Investor Conferences
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/28/2022 09/29/2022 09/30/2022 10/03/2022 10/04/2022 Date
6.25(c) 5.58(c) 6(c) 6.01(c) 6.46 Last
1 180 112 1 040 542 1 690 400 877 139 948 420 Volume
+4.52% -10.72% +7.53% +0.17% +7.49% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -356 M - -
Net cash position 2022 130 M - -
P/E ratio 2022 -3,28x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -511 M - -
Net cash position 2023 326 M - -
P/E ratio 2023 -2,73x
Yield 2023 -
Capitalization 1 218 M 1 218 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 463
Free-Float 88,7%
More Financials
Company
Sana Biotechnology, Inc. is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic... 
More about the company
Ratings of Sana Biotechnology, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about SANA BIOTECHNOLOGY, INC.
09/13Transcript : Sana Biotechnology, Inc. Presents at Morgan Stanley 20th Annual ..
CI
09/09Sana Biotechnology to Present at September 2022 Investor Conferences
GL
09/09Sana Biotechnology to Present at September 2022 Investor Conferences
AQ
08/04Sana Biotechnology : Reports Second Quarter 2022 Financial Results and Business Updates - ..
PU
08/04Sana : Q2 Earnings Snapshot
AQ
08/04SANA BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
08/04Earnings Flash (SANA) SANA BIOTECHNOLOGY Reports Q2 Loss $-0.47
MT
08/04Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
GL
08/04Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
AQ
08/04Sana Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
07/06Top Premarket Decliners
MT
06/24Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from R..
CI
06/24Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from R..
CI
06/24Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from R..
CI
06/24Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from R..
CI
More news
News in other languages on SANA BIOTECHNOLOGY, INC.
08/04Sana Biotechnology, Inc. annonce ses résultats pour le deuxième trimestre et les six mo..
06/17Les données de Sana Biotechnology montrent la survie des types de cellules transplantée..
06/17Sana Biotechnology, Inc. Présente des données lors de la réunion annuelle de l'ISSCR 20..
06/02Sana Biotechnology, Inc. annonce des nominations au conseil d'administration
05/10Sana Biotechnology, Inc. annonce ses résultats pour le premier trimestre clos le 31 mar..
More news
Analyst Recommendations on SANA BIOTECHNOLOGY, INC.
More recommendations
ETFs positioned on SANA BIOTECHNOLOGY, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ETFs S&P Biotech ETF - Distributing - AUD0.66%6.43%-United_States
SPDR S&P Biotech ETF - USD0.63%3.48%United_States
Invesco Nasdaq Biotechnology ETF - USD0.14%5.33%-United_States
IShares Nasdaq US Biotechnology (D) - USD0.13%5.76%United_States
IShares Nasdaq US Biotechnology - USD0.13%5.45%United_States
More ETFs positioned on SANA BIOTECHNOLOGY, INC.
Chart SANA BIOTECHNOLOGY, INC.
Duration : Period :
Sana Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 6,46 $
Average target price 12,75 $
Spread / Average Target 97,4%
EPS Revisions
Managers and Directors
Steven D. Harr President & Chief Executive Officer
Nathan Hardy Chief Financial Officer
Hans Edgar Bishop Chairman
Chuck Murry Senior VP-Cardiac Cell Therapy Research
Edward J. Rebar Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
SANA BIOTECHNOLOGY, INC.-58.27%1 133
MODERNA, INC.-50.52%47 331
LONZA GROUP AG-35.56%36 715
IQVIA HOLDINGS INC.-31.56%34 728
SEAGEN INC.-9.98%25 397
ALNYLAM PHARMACEUTICALS, INC.16.05%23 620